[1]
Scortichini, M., Ruggieri, A., Cattaneo, A., Mascagni, P. and Sciattella, P. 2025. Cost-analysis from real-world REDS study on dalbavancin in inpatient treatment of acute bacterial skin and skin structure infections. Global and Regional Health Technology Assessment. 12, 1 (Jun. 2025), 151–157. DOI:https://doi.org/10.33393/grhta.2025.3363.